Healthcare Apr 19, 2022 07:44 AM (GMT+8) · EqualOcean
China biopharmaceutical announced on the Hong Kong stock exchange that the self-developed anti-tumor drug "androtinib hydrochloride capsule" has obtained the drug registration certificate issued by China's State Drug Administration, and the indication is locally advanced or metastatic differentiated thyroid cancer (rair-dtc) resistant to inoperable iodine treatment. This is the fifth indication approved for arotinib after advanced non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer and medullary thyroid cancer. Enrotinib was approved for rair-dtc indication this time, and it is the first domestic original research targeted innovative drug approved for this indication. The group is making extensive arrangements for the combination of arotinib with chemotherapy, PD-1 and PD-L1. At present, more than 20 clinical trials of arotinib have entered phase II or phase III clinical trials.
Related companies: